RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.44
−3.69%Year over year
Reported trailing growth
- Revenue
- +198.5%
- EBITDA
- -50.8%
- EBIT
- -19.1%
- EPS
- +17.9%
- Free cash flow
- -15.7%
- Operating cash flow
- -15.1%
Forward estimates
Based on analyst estimates
- Revenue
- +326.2%
- EBITDA
- +27.1%
- EPS
- +39.7%
Three-year CAGR
- Revenue
- +2511.6%
- EBITDA
- -26.7%
- EBIT
- -14.0%
- Net income
- -26.7%
- EPS
- +13.5%
- Free cash flow
- -20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026